메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Our goal was to evaluate the effects and safety of aripiprazole after switching from prior antipsychotic drugs in patients with chronic schizophrenia. Neurocognitive tests were applied to 21 schizophrenic patients. The schizophrenic patients were retested with the same instruments after 8 and 24 weeks of treatment with aripiprazole. Effects were assessed using the Brief Psychiatric Rating Scale (BPRS), the Hamilton Rating Scale-Depression (HAM-D), and the Clinical Global Impression-Severity (CGI-S). Extrapyramidal symptoms were assessed using the Simpson-Angus Scale (SAS). Levels of prolactin and body weight were also measured. After switching to aripiprazole, no significant changes were observed on the BPRS, the HAM-D, or the GI-S. Significant improvements were found on the Hopkins Verbal Learning Test (HVLT), the Rey Complex Figure Test (RCFT), the Digit Span Forward, Trail-Making Test A, Korean version-Boston Naming Test (K-BNT) 24 weeks after switching to aripiprazole. Aripiprazole induced significant loss of body weight at 4 weeks and decreased prolactin levels at 8 weeks but no changes were observed in the Simpson-Angus Scale (SAS) and body weight at 24 weeks. These data suggest that aripiprazole is effective in improving verbal memory and attention. The drug also demonstrated a favorable safety profile, as observed in the low incidence of hyperprolactinemia.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0